<DOC>
	<DOCNO>NCT00594373</DOCNO>
	<brief_summary>Topical microbicides , substance kill microbe , study prevent sexual transmission HIV disease-causing agent . In future , topical microbicides may apply vaginally prevent acquisition transmission HIV sexually transmit infection ( STIs ) . The purpose study ass whether measurable response daily application topical microbicide , 1 % tenofovir gel , woman low risk HIV infection .</brief_summary>
	<brief_title>Interventional Study Mucosal Antimicrobial Responses Repeated Vaginal Applications Tenofovir Gel HIV Uninfected Women</brief_title>
	<detailed_description>A new approach HIV prevention currently study use topical microbicides . This study measure mucosal response daily intravaginal application 1 % tenofovir gel versus placebo two group woman low risk HIV infection . The duration study participant 21 day . Study participant randomly assign one two study group . Group 1 participant apply 1 % tenofovir gel daily 14 consecutive day menses . Group 2 participant apply placebo gel 14 consecutive day menses . Study visit occur Days 3 , 7 , 14 , 21 . Study entry occur 2 6 day follow menses within 30 day screen . Medical sexual history , pelvic exam , cervicovaginal lavage sample collection , blood collection , vaginal pH testing , STI testing , adverse effect report occur visit . All participant ask complete diary throughout study ; diary review study visit . A Pap smear obtain screen documentation negative Pap smear result within last year available .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Normal menstrual history regular cycle minimum 21 day menses Sexually abstinent stable , mutually monogamous relationship partner HIV uninfected Agree abstain sexual intercourse use vaginal product within 48 hour study entry duration study HIV infect Sexually transmit infection within 6 month study entry Use nontherapeutic intravenous drug within 12 month study entry Menopausal Currently use hormonal contraception use hormonal contraception within 2 month study entry Menstruating screen enrollment visit Positive urine culture Positive chlamydia , gonorrhea , trichomonas result screen Abnormal Pap smear Clinically detectable genital abnormality . More information criterion find protocol . History toxic shock syndrome history symptom suggest toxic shock syndrome History intermenstrual bleeding within 3 month study entry Previous gynecologic surgery receive treatment syphilis , genital herpes , chlamydia , gonorrhea , trichomonas , genital wart within 6 month study entry Received treatment Candida , bacterial vaginosis , urinary tract infection within 1 month study entry Have douche use vaginal product , include lubricant , feminine hygiene product , vaginal drying agent , sex toy within 48 hour study entry Acute chronic hepatitis B virus infection Liver kidney abnormality Oral antibiotic within 7 day study entry Pregnant , less 6 month postpartum , breastfeed</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Microbicide</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>